Fundraising Fox

Omeicos Therapeutics

Founded 2013 · 3 known investors

omeicos.com ↗

OMEICOS develops small-molecule therapies based on omega-3 fatty acid metabolism that target cell-protective pathways to treat cardiovascular, inflammatory, and mitochondrial diseases. Its lead compound OMT-28 has been evaluated in Phase 2 clinical trials, including for atrial fibrillation and primary mitochondriopathies.

BiotechHealthtech

Investors · 3

Remiges Ventures, Inc.Seattle
Vesalius Biocapital PartnersLuxembourg · $11M
ForbionreportedNaarden

In the news

German biopharma company Omeicos Therapeutics snags Series C fundingventurecapitaljournal.com · Nov 2018Forbion leads €17m series-C for Omeicos | Unquoteunquote.com · Nov 2018Omeicos raises €17M to run phase 2 atrial fibrillation trial | Fierce Biotechfiercebiotech.com · Nov 2018Omeicos Raises Series B Financing Round Extension - FinSMEsfinsmes.com · Oct 2017Omeicos Therapeutics Raises €6.2M in Series A Funding | FinSMEsfinsmes.com · Apr 2015

Frequently asked questions

What does Omeicos Therapeutics do?
OMEICOS develops small-molecule therapies based on omega-3 fatty acid metabolism that target cell-protective pathways to treat cardiovascular, inflammatory, and mitochondrial diseases. Its lead compound OMT-28 has been evaluated in Phase 2 clinical trials, including for atrial fibrillation and primary mitochondriopathies.
Who are Omeicos Therapeutics's investors?
Omeicos Therapeutics's investors include Remiges Ventures, Inc., Vesalius Biocapital Partners, Forbion.